Caprion, Vertex Enter Biomarker Discovery Pact

Caprion Pharmaceuticals’ Applied BioMedicine group has entered a research collaboration with Vertex Pharmaceuticals. The collaboration will use Caprion’s CellCarta proteomics platform to support clinical biomarker discovery. Caprion will identify potential pharmacodynamic biomarkers in samples from certain clinical and preclinical studies conducted by Vertex.

“Caprion is looking forward to working with Vertex on this clinical biomarker discovery collaboration,” said Dr. Daniel Chelsky, chief scientific officer at Caprion. “We believe that Caprion’s capabilities in the discovery of protein biomarkers may significantly impact development efforts for one or more Vertex compounds.”

Caprion’s proprietary proteomics platform comprehensively profiles proteins and provides an unprecedented level of protein expression and identification in tissues and blood plasma. Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies and its own clinical programs.